We tested a novel small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. Proteomic analysis was performed on treated cell lines and controls to identify protein differences. Cellular thermal shift assay (CETSA) was used to determine the interaction of SU086 with proteins.
We have compared three different glycopeptide enrichment techniques (SAX-ERLIC, HILIC, and lectin affinity) and a C18 control to a tryptic digest of proteins from depleted human plasma.
We have compared three different glycopeptide enrichment techniques (SAX-ERLIC, HILIC, and lectin affinity) and a C18 control to a tryptic digest of proteins from depleted human plasma.
Synthetic analogues of chalcones were investigated as potential therapeutics for triple negative breast cancer. These analogues were used in quantitative proteomic experiments to determine the mechanism of action.
Shotgun proteomics analysis was performed on plasma samples from breast cancer patients undergoing radiotherapy (RT) treatment. Samples were obtained at 4 timepoints before, during, and after RT.
Quantitative proteomics analysis was performed on two samples of localized prostate tumors from one patient (R40) and eight samples from metastatic prostate cancer sites. One sample from the right lung, one sample from the peritoneal lymph node, and two samples from the mediastinal lymph node were c...
Quantitative proteomics analysis was performed on patient derived neuroendocrine tissue xenografts comparing sh control (N=2), and shUCHL1 (N=4), and in NCI-H660 cell line xenografts comparing control (N=3) and LDN-57444 treated (N=3). Each condition was injected in triplicate.
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human)
To identify proteomic signatures associated with hepatocellular carcinoma driven by MYC overexpression, proteomics was performed on the LAP-tTA/tetO-MYC mouse conditional liver cancer model. Upon MYC activation, mice form liver cancer. Differential proteomics was performed in "MYC on" (MYC-HCC) mous...
